Search

Your search keyword '"Fiala, Mark A"' showing total 945 results
Start Over Author "Fiala, Mark A"
945 results on '"Fiala, Mark A"'

1. IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma

Author

Sun, Jennifer, Corradini, Stefan, Azab, Feda, Shokeen, Monica, Muz, Barbara, Miari, Katerina E., Maksimos, Mina, Diedrich, Camila, Asare, Obed, Alhallak, Kinan, Park, Chaelee, Lubben, Berit, Chen, Yixuan, Adebayo, Ola, Bash, Hannah, Kelley, Sarah, Fiala, Mark, Bender, Diane E., Zhou, Haibin, Wang, Shaomeng, Vij, Ravi, Williams, Mark T. S., and Azab, Abdel Kareem

Published
2024
Full Text
View/download PDF

4. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma

Author

Pilcher, William, Thomas, Beena E., Bhasin, Swati S., Jayasinghe, Reyka G., Yao, Lijun, Gonzalez-Kozlova, Edgar, Dasari, Surendra, Kim-Schulze, Seunghee, Rahman, Adeeb, Patton, Jonathan, Fiala, Mark, Cheloni, Giulia, Kourelis, Taxiarchis, Dhodapkar, Madhav V., Vij, Ravi, Mehr, Shaadi, Hamilton, Mark, Cho, Hearn Jay, Auclair, Daniel, Avigan, David E., Kumar, Shaji K., Gnjatic, Sacha, Ding, Li, and Bhasin, Manoj

Published
2023
Full Text
View/download PDF

6. Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States.

Author

Auclair, Daniel, Mansfield, Carol, Fiala, Mark, Chari, Ajai, Cole, Craig, Kaufman, Jonathan, Orloff, Gregory, Siegel, David, Zonder, Jeffrey, Mange, Brennan, Yesil, Jennifer, Dalal, Mehul, and Mikhael, Joseph

Subjects
caregiver, discrete choice experiment, multiple myeloma, patient, preference
Abstract

INTRODUCTION/BACKGROUND: This study aimed to describe patient and caregiver preferences for treatments of relapsed or refractory multiple myeloma (MM). MATERIALS AND METHODS: A survey including discrete-choice experiment (DCE) and best-worst scaling (BWS) exercises was conducted among US patients with relapsed or refractory MM and their caregivers. The DCE included six attributes with varying levels including progression-free survival (PFS), toxicity, and mode and frequency of administration. In addition, the impact of treatment cost was assessed using a fixed-choice question. The BWS exercise included 18 items (modes and frequency of administration, additional treatment convenience, and toxicity items). The survey was administered online to patients recruited from the Multiple Myeloma Research Foundation CoMMpass study (NCT01454297). RESULTS: The final samples consisted of 94 patients and 32 caregivers. Avoiding severe nerve damage was most important to patients, followed by longer PFS. Caregivers considered PFS to be the most important attribute. We estimate that a third or more of patients were cost-sensitive, meaning their treatment preference was altered based on cost implications. Caregivers were not cost-sensitive. The three most bothersome treatment features in the BWS exercise were risk of kidney failure, lowering white blood cell counts, and weakening the immune system. CONCLUSION: Patients with relapsed or refractory MM and their caregivers consider many factors including efficacy, toxicity, mode/frequency of administration, and cost in their decisions regarding treatment options. The study provides a basis for future Research on patient and caregiver treatment preferences, which could be incorporated into shared decision-making with physicians.

Published
2022

7. Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma

Author

Schoenbeck, Kelly L, Fiala, Mark A, and Wildes, Tanya M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Aging, Patient Safety, Rare Diseases, Cancer, Prevention, Hematology, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Accidental Falls, Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Humans, Medicare, Multiple Myeloma, Prospective Studies, United States, Elderly, Geriatric assessment, Multiple myeloma, Accidental falls, Oncology and Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundBortezomib is a common multiple myeloma therapy that can cause treatment-related peripheral neuropathy, a risk factor for falls. The relationship between bortezomib and falls in older patients with multiple myeloma is unknown.MethodsWe analyzed the SEER-Medicare database for patients aged 65 or older diagnosed with multiple myeloma between 2007 and 2013. Claims were analyzed for myeloma treatments, falls, and covariates of interest. We evaluated accidental falls occurring within 12 months after starting first-line multiple myeloma treatment with bortezomib.ResultsBortezomib was used in first-line therapy for 2052 older adults with new diagnoses of multiple myeloma. Claims for falls were reported in 157 (8%) patients within 12 months after starting bortezomib, compared to 102 (5%) patients not receiving bortezomib (p

Published
2021

13. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19:CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, Aboulafia, David M, Accordino, Melissa K, Acoba, Jared D, Ahluwalia, Manmeet S, Ahmad, Syed A, Ajmera, Archana, Alimohamed, Saif I, Altman, Jessica, Angevine, Anne H, Bakouny, Ziad, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill S, Barrow McCollough, Briana, Bashir, Babar, Batist, Gerald, Bekaii-Saab, Tanios S, Berg, Stephanie, Bernicker, Eric H, Bhutani, Divaya, Bilen, Mehmet A, Bindal, Poorva, Bishnoi, Rohit, Blau, Sibel, Bohachek, Pamela, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bouganim, Nathaniel, Bowles, Daniel W, Busser, Fiona J, Butt, Omar, Cabal, Angelo, Cabalona, Wilhelmina D, Cabebe, Elwyn C, Caimi, Paolo, Campian, Jian L, Carducci, Theresa M, Chen, James L, Cheng, Alex, Chism, David D, Choueiri, Toni K, Clark, Melanie J, Clement, Jessica M, Connors, Jean M, Cook, Erin, Curran, Catherine R, Daher, Ahmad, Dailey, Mark E, Davis, Elizabeth J, Dawsey, Scott J, Deeken, John F, Del Prete, Salvatore A, Demetri, George D, Desai, Aakash, Doroshow, Deborah B, Durbin, Eric B, Egan, Pamela C, Elias, Rawad, Elkrief, Arielle, Elms, Destry J, Elshoury, Amro, Faller, Bryan, Farmakiotis, Dimitrios, Fecher, Leslie A, Feldman, Lawrence E, Ferrario, Cristiano, Fiala, Mark A, Flora, Daniel B, French, Benjamin, Friese, Christopher R, Fu, Julie C, Gadgeel, Shirish M, Gainor, Justin, Galsky, Matthew D, Gantt, Gerald, Garcia, Jorge A, Gartrell, Benjamin A, Gatti-Mays, Margaret E, Gill, David M, Gillaspie, Erin A, Giordano, Antonio, Glace, Mary Grace, Glover, Michael J, Goel, Sanjay, Graber, Jerome J, Griffiths, Elizabeth A, Grivas, Petros, Grover, Punita, Gulati, Anthony P, Gulati, Shuchi, Gupta, Shilpa, Gurley, Michael, Hafez, Navid, Halabi, Susan, Halfdanarson, Thorvardur R, Halmos, Balazs, Hausrath, Daniel J, and Hawley, Jessica E

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Clinical Research, Cancer, COVID-19, COVID-19 Testing, Data Accuracy, Electronic Health Records, Humans, Neoplasms, Quality Improvement, SARS-CoV-2, COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org, COVID-19 and Cancer Consortium, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020

16. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.

Author

Fakhri, Bita, Fiala, Mark A, Shah, Nina, Vij, Ravi, and Wildes, Tanya M

Subjects
Humans, Multiple Myeloma, Lung Diseases, Heart Diseases, Oligopeptides, SEER Program, Risk Factors, International Classification of Diseases, Databases, Factual, Adult, Aged, Aged, 80 and over, Middle Aged, Medicare, United States, Female, Male, Epidemiology, Surveillance, and End Results (SEER)-Medicare linked database, cardiopulmonary complications, carfilzomib, multiple myeloma, older adults, Patient Safety, Cardiovascular, Hematology, Clinical Research, Rare Diseases, Aging, Lung, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Respiratory, Epidemiology and End Results (SEER)-Medicare linked database, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundCarfilzomib improves survival in patients with recurrent myeloma. Given the strict eligibility criteria in clinical trials, the actual frequency of cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) and the risk factors associated with these AEs in the general population need to be established.MethodsThe authors extracted myeloma cases in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database from 2000 through 2013 and corresponding claims through 2014. They then identified patients who received carfilzomib during their disease course. Subsequently, the International Classification of Diseases, Ninth Revision (ICD-9) was used to identify all the codes for CAEs, PAEs, and respiratory infections associated with carfilzomib use. Preexisting diagnoses corresponding to the CAEs and PAEs of interest were excluded to distinguish toxicity from comorbidity. Multivariate Cox regression was performed to determine those variables independently associated with the development of CAEs and PAEs.ResultsOf the 635 patients analyzed, the median age was 72 years (range, 36-94 years); 55% of the patients were male and 79% were white. The median duration of carfilzomib treatment was 58 days (range, 1-716 days). Overall, approximately 66% of the patients had codes for either CAEs or PAEs. In terms of CAEs, approximately 22% of patients developed hypertension, 15% developed peripheral edema, and 14% experienced heart failure. With regard to PAEs, approximately 28% of patients developed dyspnea, 15% developed cough, and 15% developed pneumonia. Only chronic obstructive pulmonary disease (COPD) was found to be independently associated with the development of CAEs. Patients with preexisting COPD were found to have a 40% increase in their hazard of developing CAEs (adjusted hazard ratio, 1.40; 95% CI, 1.03-1.90).ConclusionsIn older adults with myeloma who are undergoing treatment with carfilzomib, new cardiac and pulmonary diagnoses were common. Patients with preexisting COPD were found to be at an increased risk of developing CAEs.

Published
2020

17. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Author

Du, Zhaohui, Weinhold, Niels, Song, Gregory Chi, Rand, Kristin A, Van Den Berg, David J, Hwang, Amie E, Sheng, Xin, Hom, Victor, Ailawadhi, Sikander, Nooka, Ajay K, Singhal, Seema, Pawlish, Karen, Peters, Edward S, Bock, Cathryn, Mohrbacher, Ann, Stram, Alexander, Berndt, Sonja I, Blot, William J, Casey, Graham, Stevens, Victoria L, Kittles, Rick, Goodman, Phyllis J, Diver, W Ryan, Hennis, Anselm, Nemesure, Barbara, Klein, Eric A, Rybicki, Benjamin A, Stanford, Janet L, Witte, John S, Signorello, Lisa, John, Esther M, Bernstein, Leslie, Stroup, Antoinette M, Stephens, Owen W, Zangari, Maurizio, Van Rhee, Frits, Olshan, Andrew, Zheng, Wei, Hu, Jennifer J, Ziegler, Regina, Nyante, Sarah J, Ingles, Sue Ann, Press, Michael F, Carpten, John David, Chanock, Stephen J, Mehta, Jayesh, Colditz, Graham A, Wolf, Jeffrey, Martin, Thomas G, Tomasson, Michael, Fiala, Mark A, Terebelo, Howard, Janakiraman, Nalini, Kolonel, Laurence, Anderson, Kenneth C, Le Marchand, Loic, Auclair, Daniel, Chiu, Brian C-H, Ziv, Elad, Stram, Daniel, Vij, Ravi, Bernal-Mizrachi, Leon, Morgan, Gareth J, Zonder, Jeffrey A, Huff, Carol Ann, Lonial, Sagar, Orlowski, Robert Z, Conti, David V, Haiman, Christopher A, and Cozen, Wendy

Subjects
Hematology, Rare Diseases, Genetics, Cancer, Clinical Research, Prevention, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Female, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Multiple Myeloma, Polymorphism, Single Nucleotide, Transcriptional Elongation Factors
Abstract

Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of EA. Little is known about genetic risk factors for MM in individuals of AA. We performed a meta-analysis of 2 GWASs of MM in 1813 cases and 8871 controls and conducted an admixture mapping scan to identify risk alleles. We fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. In GWAS meta-analysis, we identified 2 suggestive novel loci located at 9p24.3 and 9p13.1 at P < 1 × 10-6; however, no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. Of the 23 known EA risk variants, 20 showed directional consistency, and 9 replicated at P < .05 in AA individuals. In 8 regions, we identified markers that better capture MM risk in persons with AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95% confidence interval, 1.56-2.11) increased MM risk compared with those with average risk (25%-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P = 5.1 × 10-12). Our study shows that common genetic variation contributes to MM risk in individuals with AA.

Published
2020

20. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma

Author

Barnell, Erica K., Skidmore, Zachary L., Newcomer, Kenneth F., Chavez, Monique, Campbell, Katie M., Cotto, Kelsy C., Spies, Nicholas C., Ruzinova, Marianna B., Wang, Tianjiao, Abro, Brooj, Kreisel, Friederike, Parikh, Bijal A., Duncavage, Eric J., Frater, John L., Lee, Yi-Shan, Hassan, Anjum, King, Justin A., Kohnen, Daniel R., Fiala, Mark A., Welch, John S., Uy, Geoffrey L., Vij, Kiran, Vij, Ravi, Griffith, Malachi, Griffith, Obi L., and Wartman, Lukas D.

Published
2023
Full Text
View/download PDF

23. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

Author

Costa, Luciano J., Lin, Yi, Cornell, R. Frank, Martin, Thomas, Chhabra, Saurabh, Usmani, Saad Z., Jagannath, Sundar, Callander, Natalie S., Berdeja, Jesus G., Kang, Yubin, Vij, Ravi, Godby, Kelly N., Malek, Ehsan, Neppalli, Amarendra, Liedtke, Michaela, Fiala, Mark, Tian, Hong, Valluri, Satish, Marino, Jennifer, Jackson, Carolyn C., Banerjee, Arnob, Kansagra, Ankit, Schecter, Jordan M., Kumar, Shaji, and Hari, Parameswaran

Published
2022
Full Text
View/download PDF

24. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis

Author

Jurczyszyn, Artur, Castillo, Jorge J., Olszewska-Szopa, Magdalena, Kumar, Lalit, Thibaud, Santiago, Richter, Joshua, Flicker, Kari, Fiala, Mark, Vij, Ravi, Yi, Shuhua, Xu, Fang, Silbermann, Rebecca, Gaisan, Carmen Montes, Ocio, Enrique M., Waszczuk-Gajda, Anna, Crusoe, Edvan De Queiroz, Salomon-Perzyński, Aleksander, Hus, Iwona, Valls, Julio Davila, Gozzetti, Alessandro, Czepiel, Jacek, Krzanowska, Katarzyna, Chappell, Aimee, Chellapuram, S.K, Suska, Anna, and Vesole, David H.

Published
2022
Full Text
View/download PDF

27. Financial Toxicity and Willingness-to-Pay for Cancer Treatment Among People With Multiple Myeloma.

Author

Fiala, Mark A.

Subjects
MULTIPLE myeloma treatment, STATISTICAL correlation, MULTIPLE myeloma, ACADEMIC medical centers, THERAPEUTICS, RESEARCH funding, STATISTICAL sampling, QUESTIONNAIRES, MULTIPLE regression analysis, DESCRIPTIVE statistics, MANN Whitney U Test, MULTIVARIATE analysis, AGE distribution, FINANCIAL stress, RACE, ODDS ratio, ATTITUDE (Psychology), RESEARCH, STATISTICS, PATIENT decision making, CANCER patient psychology, PROGRESSION-free survival, HEALTH equity, DATA analysis software, CONFIDENCE intervals, MEDICAL care costs, PATIENTS' attitudes
Abstract

PURPOSE: This study used willingness-to-pay (WTP) exercises to explore the relationships between race, financial toxicity, and treatment decision making among people with cancer. METHODS: A convenience sample of people with multiple myeloma who attended an academic medical center in 2022 was surveyed. Financial toxicity was assessed by the Comprehensive Score for financial Toxicity, with scores <26 indicating financial toxicity. WTP was assessed with (1) a discrete choice experiment (DCE), (2) fixed-choice tasks, and (3) a bidding game. RESULTS: In total, 156 people were approached, and 130 completed the survey. The majority of the sample was White (n = 99), whereas 24% (n = 31) was African American or Black. Forty-six percent (n = 60) of the sample were experiencing financial toxicity. In the DCE, the relative importance of cost was twice as high for those with financial toxicity (30% compared with 14%; P <.001). In the fixed-choice tasks, they were twice as likely to accept a treatment with shorter progression-free survival but lower costs (adjusted odds ratio [aOR], 2.47; P =.049). In the bidding game, the median monthly WTP of those with financial toxicity was half that of those without ($100 in US dollars [USD] compared with $200 USD; P <.001). Only in the bidding game was race statistically associated with WTP; after controlling for financial toxicity, African American or Black participants were three times as likely (aOR, 3.06; P =.007) to report a lower WTP. CONCLUSION: Across all three exercises, participants with financial toxicity reported lower WTP than those without. As financial toxicity disproportionally affects some segments of patients, it is possible that financial toxicity contributes to cancer disparities. Dr Fiala assessed the importance of treatment cost in selecting treatments for people with cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. #27. First-in-human evaluation of safety and dosimetry of 64Cu-LLP2A for PET imaging

Author

Laforest, Richard, primary, Ghai, Anchal, additional, Fraum, Tyler J., additional, Oyama, Reiko, additional, Frye, Jennifer, additional, Kaemmerer, Helen, additional, Gaehle, Greg, additional, Voller, Tom, additional, Mpoy, Cedric, additional, Rogers, Buck E., additional, Fiala, Mark, additional, Shoghi, Kooresh I., additional, Achilefu, Samuel, additional, Rettig, Michael, additional, Vij, Ravi, additional, DiPersio, John F., additional, Schwarz, Sally, additional, Shokeen, Monica, additional, and Dehdashti, Farrokh, additional

Published
2024
Full Text
View/download PDF

44. Co-evolution of tumor and immune cells during progression of multiple myeloma

Author

Liu, Ruiyang, Gao, Qingsong, Foltz, Steven M., Fowles, Jared S., Yao, Lijun, Wang, Julia Tianjiao, Cao, Song, Sun, Hua, Wendl, Michael C., Sethuraman, Sunantha, Weerasinghe, Amila, Rettig, Michael P., Storrs, Erik P., Yoon, Christopher J., Wyczalkowski, Matthew A., McMichael, Joshua F., Kohnen, Daniel R., King, Justin, Goldsmith, Scott R., O’Neal, Julie, Fulton, Robert S., Fronick, Catrina C., Ley, Timothy J., Jayasinghe, Reyka G., Fiala, Mark A., Oh, Stephen T., DiPersio, John F., Vij, Ravi, and Ding, Li

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results